Key Points
- Director David Pelizzon sold 302,369 OrthoPediatrics shares at an average price of $21.01, generating approximately $6.35 million. His remaining stake fell 4.65% to 6.20 million shares.
- OrthoPediatrics reported quarterly revenue of $70.51 million and an adjusted loss of $0.26 per share, beating analyst expectations for both metrics. The stock opened at $21.56, with a market capitalization of about $563 million.
- Analyst sentiment remains generally positive, with nine Buy ratings, one Hold and one Sell; the consensus rating is Moderate Buy with an average price target of $26.44. Institutional investors own approximately 69.05% of the company.
OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) Director David Pelizzon sold 302,369 shares of the company's stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the sale, the director directly owned 6,201,764 shares of the company's stock, valued at approximately $130,299,061.64. This trade represents a 4.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
OrthoPediatrics Trading Down 0.6%
NASDAQ:KIDS opened at $21.56 on Friday. The company has a market capitalization of $562.93 million, a PE ratio of -12.83 and a beta of 0.99. OrthoPediatrics Corp. has a 52-week low of $14.42 and a 52-week high of $26.74. The stock's 50 day moving average price is $21.97 and its 200 day moving average price is $19.02. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28.
OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. The company had revenue of $70.51 million during the quarter, compared to analysts' expectations of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. On average, research analysts anticipate that OrthoPediatrics Corp. will post -1.14 EPS for the current year.
Analyst Ratings Changes
Several analysts recently commented on the stock. Weiss Ratings upgraded shares of OrthoPediatrics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, August 5th. Truist Financial set a $22.00 price objective on shares of OrthoPediatrics in a research report on Wednesday, August 5th. BTIG Research lifted their price objective on shares of OrthoPediatrics from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Thursday, August 20th. Piper Sandler reaffirmed an "overweight" rating and issued a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Finally, Needham & Company LLC increased their target price on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $26.44.
Get Our Latest Stock Report on KIDS
Institutional Investors Weigh In On OrthoPediatrics
Several large investors have recently modified their holdings of KIDS. Millennium Management LLC grew its position in OrthoPediatrics by 48.0% in the 4th quarter. Millennium Management LLC now owns 1,396,495 shares of the company's stock valued at $24,802,000 after buying an additional 452,840 shares during the last quarter. BlackRock Inc. purchased a new position in OrthoPediatrics during the 2nd quarter worth $24,347,000. Vanguard Group Inc. raised its position in OrthoPediatrics by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 961,330 shares of the company's stock worth $17,813,000 after buying an additional 10,927 shares during the last quarter. Granahan Investment Management LLC lifted its stake in shares of OrthoPediatrics by 35.1% in the 1st quarter. Granahan Investment Management LLC now owns 896,741 shares of the company's stock worth $14,231,000 after acquiring an additional 232,760 shares during the period. Finally, Wasatch Advisors LP lifted its stake in shares of OrthoPediatrics by 56.6% in the 2nd quarter. Wasatch Advisors LP now owns 515,677 shares of the company's stock worth $9,865,000 after acquiring an additional 186,357 shares during the period. Hedge funds and other institutional investors own 69.05% of the company's stock.
About OrthoPediatrics
(
Get Free Report)
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
